Universitätsklinikum Schleswig-Holstein (UKSH)

Facial trauma management: A nationwide data collection on practice patterns and patient care in oral and maxillofacial surgery in Germany (2025) Becker P, Bouffleur F, Heimes D, Thiem DG, Seifert LB, Neff A, Wiltfang J, et al. Journal article Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. (2025) Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, et al. Journal article Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg. (2025) Forschner A, Kähler KC, Gschnell M, Langan EA, Weishaupt C, Meiss F, Thoms KM, et al. Journal article The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML (2025) Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, et al. Journal article Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status (2025) Placke JM, Rajcsanyi LS, Herbst R, Terheyden P, Utikal J, Pföhler C, Kreuter A, et al. Journal article Preferred Working Time Models and Equal Opportunities in Gynecology and Obstetrics: Results of the Systematic Trinational FARBEN Survey Favorisierte Arbeitszeitmodelle und Gleichberechtigung in der Gynakologie und Geburtshilfe: die Ergebnisse der systematischen trinationalen FARBEN-Umfrage (2025) Tauber N, Amann N, Foessleitner P, Klee A, Becker C, Kiblawi R, Göpfert M, et al. Journal article Implant-based reconstruction and adjuvant radiotherapy in breast cancer patients—current status and DEGRO recommendations (2025) Piroth MD, Krug D, Baumann R, Strnad V, Borm K, Combs S, Corradini S, et al. Journal article Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. (2025) Sähn MJ, Wienke A, Meyer HJ, Dietz J, Vogl TJ, Borggrefe J, Gussew A, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)] (2025) Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, et al. Journal article, Erratum